CAMBRIDGE, Mass.– Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, has strengthened its leadership team with the appointment of two industry veterans ahead of its upcoming pivotal trial studies.
The company announced that Dr. Richard Fahrner has joined as Chief Technology Officer, while Dr. Tamara Agajanov, M.D., has been named Senior Vice President of Clinical Development.
Dr. Fahrner brings more than 25 years of experience in drug development, most recently serving as head of pharmaceutical development at Ra Pharmaceuticals, acquired by UCB in a $2.5 billion transaction. His prior roles include leadership positions at Catabasis, Pfizer, Sanofi, and Gilead. Over his career, he has contributed to the development of more than 17 approved medicines, including Vpriv and Elaprase, which were granted accelerated approvals by the U.S. Food and Drug Administration. He earned his Ph.D. in Biochemistry and Molecular Biology from UCLA.
Dr. Agajanov has nearly three decades of experience in clinical operations and development, with expertise in oncology, immunology, and inflammation. She previously served as Senior Vice President of Global Clinical Operations at Neurvati Neurosciences, Vice President of Clinical Operations at Ovid Therapeutics, Therapeutic Area Head of Oncology at Boehringer Ingelheim, and Associate Director at Roche. Her leadership has helped advance multiple programs into late-stage clinical development.
“Both Dr. Fahrner and Dr. Agajanov have led the development of multiple products during their long careers, and their expertise in accelerated approvals aligns with our strategy of designing robust but cost-efficient trials,” said Dr. Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Founder of Vyome. “We are delighted that both Dr. Agajanov and Dr. Fahrner decided to join the Vyome team, significantly bolstering our depth in developing next-generation therapies as we embark on pivotal studies with our leading asset.”
Vyome is currently conducting a Phase 2 study in malignant fungating wounds (MFW), which the company describes as a potential multi-billion-dollar market opportunity. Topline results from the study are expected in October 2025.
“I am excited to join Vyome at this critical stage. The company has assembled a strong pipeline of scientifically and clinically validated programs that can create tremendous value in the near term,” said Dr. Fahrner. “The interim Phase 2 results in MFW are very encouraging, and this is an opportunity to develop a first-in-class therapy for patients with limited treatment options.”
Venkat Nelabhotla, CEO of Vyome, said the appointments mark a turning point for the company. “The addition of these leaders marks an important milestone in Vyome’s growth journey. We are now properly capitalized and have the right team in place to unlock the next milestones of value in our lead programs,” he said. “Dr. Fahrner and Dr. Agajanov’s proven track records in drug development and clinical leadership add depth to our goal of creating shareholder value, especially given the promising interim Phase 2 data in malignant fungating wounds.”
